目的 探讨过敏性鼻炎（AR）及其干预对儿童系统性红斑狼疮（JSLE）病情和治疗用药的影响。方法 收集96例确诊的JSLE患儿临床资料，按是否合并过敏性鼻炎或其他过敏性疾病分为过敏性鼻炎组（44例）和非鼻炎过敏组（20例），以及非过敏组（32例），过敏性鼻炎组又随机分为鼻炎干预组和非干预组（各22例）。所有患儿均进行规范JSLE治疗。比较各组患儿的SLE疾病活动性指数（SLEDAI）和激素、免疫抑制剂用药情况。结果 合并过敏性鼻炎组和非鼻炎过敏组的JSLE患儿治疗前的SLEDAI评分、糖皮质激素日累积剂量、免疫抑制剂用药种数均高于非过敏组（P < 0.05），而过敏性鼻炎组和非鼻炎过敏组间的差异无统计学意义（P > 0.05）。治疗1个月后，JSLE合并过敏性鼻炎患儿干预组的SLEDAI评分及激素日累积剂量低于非干预组（P < 0.05），两组患儿免疫抑制剂用药种数的差异无统计学意义（P > 0.05）；治疗3个月及6个月后，干预组的SLEDAI评分、激素日累积剂量、免疫抑制剂使用种类均少于非干预组（P < 0.05）。结论 JSLE合并AR等过敏性疾病可能对SLE病情及治疗产生不利影响；针对AR给予干预有利于病情控制。
Abstract
Objective To investigate the effect of allergic rhinitis (AR) and its intervention on disease condition and medications in patients with juvenile-onset systemic lupus erythematosus (JSLE). Methods The clinical data of 96 children diagnosed with JSLE were collected, and according to the presence or absence of AR or other allergic diseases, they were divided into AR group (n=44), non-AR group (n=20), and non-allergic group (n=32). The children in the AR group were randomly administered with or without intervention (n=22 each). All the children were given standard JSLE treatment. The systemic lupus erythematosus disease active index (SLEDAI) and application of hormones and immunosuppressants were compared between groups. Results The AR and non-AR groups had significantly higher SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants used than the non-allergic group before treatment (P < 0.05), while there were no significant differences between the AR and non-AR groups (P > 0.05). After one month of treatment, the AR group with intervention had significantly lower SLEDAI scores and daily cumulative doses of glucocorticoids than the AR group without intervention (P < 0.05), while there was no significant difference in the application of immunosuppressants between these two groups (P > 0.05). After 3 and 6 months of treatment, the AR group with intervention had significantly lower SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants than the AR group without intervention (P < 0.05). Conclusions JSLE combined with allergic diseases such as AR has an adverse effect on disease condition and treatment, and the intervention for AR helps with the control of JSLE.
关键词
过敏性鼻炎 /
系统性红斑狼疮 /
儿童
Key words
Allergic rhinitis /
Systemic lupus erythematosus /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Chen YM, Lin CH, Chen HH, et al. Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients:a nationwide population-based study in Taiwan[J]. Rheumatology (Oxford), 2014, 53(1):180-185.
[2] Goldman JA, Klimek GA, Ali R. Allergy in systemic lupus erythematosus. IgE levels and reaginic phenomenon[J]. Arthritis, Rheum, 1976, 19(4):669-676.
[3] Hsiao YP, Tsai JD, Muo CH, et al. Atopic diseases and systemic lupus erythematosus:an epidemiological study of the risks and correlations[J]. Int J Environ Res Public Health, 2014, 11(8):8112-8122.
[4] 李博, 叶志中. 系统性红斑狼疮[M]//叶志中, 李博, 何伟珍. 儿童风湿病学. 北京:人民卫生出版社, 2009:193-214.
[5] Kuhn A, Bonsmann G, Anders HJ, et al. The diagnosis and treatment of systemic lupus erythematosus[J]. Dtsch Arztebl Int, 2015, 112(25):423-432.
[6] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组, 中华儿科杂志编辑委员会.儿童变应性鼻炎诊断和治疗指南(2010年, 重庆)[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(1):7-8.
[7] Rao V, Gordon C. Advances in the assessment of lupus disease activity and damage[J]. Curr Opin Rheumatol, 2014, 26(5):510-519.
[8] Tavangar-Rad F, Ziaee V, Moradinejad MH, et al. Morbidity and mortality in Iranian children with juvenile systemic lupus erythematosus[J]. Iran J Pediatr, 2014, 24(4):365-370.
[9] Wilke CM, Bishop K, Fox D, et al. Deciphering the role of Th17 cells in human disease[J]. Trends Immunol, 2011, 32(12):603-611.
[10] Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ:receptors, functions, and roles in diseases[J]. J Allergy Clin Immunol, 2011, 127(3):701-721.e70.
[11] Shen TC, Tu CY, Lin CL, et al. Increased risk of asthma in patients with systemic lupus erythematosus[J]. Am J Respir Crit Care Med, 2014, 189(4):496-499.
[12] Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus[J]. Clin Immunol, 2014, 154(1):1-12.
[13] Xuekun H, Qintai Y, Yulian C, et al. Correlation of gammadelta-T-cells, Th17 cells and IL-17 in peripheral blood of patients with allergic rhinitis[J]. Asian Pac J Allergy Immunol, 2014, 32(3):235-239.
[14] 黄雪琨,杨钦泰,陈玉莲,等. γδ T细胞、调节性T细胞、白细胞介素17及转化生长因子β1在变应性鼻炎患者外周血中的表达[J]. 中华耳鼻咽喉头颈外科杂志, 2013, 48(7):544-548.
[15] Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169):566-569.
[16] Cai Z, Wong CK, Dong J, et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large(MRL)/lpr mice[J]. Clin Exp Immunol, 2015, 181(2):253-266.
[17] 丁莲富, 陈强,李岚,等. 舌下特异性免疫治疗过敏性鼻炎/过敏性哮喘患儿IL-17和IL-35水平的变化及临床疗效[J]. 中国当代儿科杂志, 2014, 16(12):1206-1210.
[18] 何珂骏. 特应性体质对常见儿童风湿病病情的影响[D]. 上海:上海交通大学, 2009.
[19] Leng RX, Pan HF, Ye DQ, et al. Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus[J]. Am J Clin Exp Immunol, 2012, 1(1):28-32.
[20] Yang J, Li Q, Yang X, et al. Interleukin-9 is associated with elevated anti-double-stranded DNA antibodies in lupus-prone mice[J]. Mol Med, 2015, 21:364-370.
[21] Wang XQ, Hu GH, Kang HY, et al. High frequency of T helper type 9 cells in Chinese patients with allergic rhinitis[J]. Asian Pac J Allergy Immunol, 2015, 33(4):301-307.
PDF(1219 KB)
